7. Development of an internship program for students in schools of public health to learn about the federal public health system. For example, developing an internship and mentoring program for masters of public health and masters of health sciences students during their academic preparation.

Federal Involvement

The Cooperative Agreement mechanism is being used for this project to allow for substantive Federal programmatic involvement in the development of the details of the Cooperative Agreement.

Substantive Federal programmatic involvement will occur through Federal membership on the Steering Committee representing the Health Resources and Services Administration, including the Bureau of Health Professions, Bureau of Health Resources Development, Bureau of Primary Health Care, Maternal and Child Health Bureau, and the Office of Public Health Practice. The involvement primarily would be in the following areas:

- participation in the identification of emerging health management practice issues for technical assistance purposes;
- identification of HRSA programmatic issues for special attention through the Cooperative Agreement;
- identification of appropriate consultation for the proposed projects;
- assistance in defining the objective, method, evaluation and use of project results and translation into the knowledge, skills, and attributes for educational objectives;
- assistance in ensuring appropriate linkages with public health practice and health care delivery sites;
- assistance in creating linkages to appropriate professional associations in the Washington, D.C. area;
- participation in the review and selection of contracts and agreements developed in implementing the project; (and)
- participation in monitoring the implementation, conduct and results of projects implemented under the Cooperative Agreement.

Eligibility for Funding

Entities eligible for funding under this Cooperative Agreement must:

1. be a recognized professional association representing schools of public health, and

2. be located in the Washington, D.C. metropolitan area.

National Health Objectives for the Year 2000

The Public Health Service (PHS) urges applicants to submit work plans that address specific objectives of *Healthy People 2000*. Potential applicants may obtain a copy of *Healthy People 2000* (Full Report; Stock No. 017–001–00474–0) or *Healthy People 2000* (Summary Report; Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402–9325 (Telephone (202) 783–3238).

Education and Service Linkage

As part of its long-range planning, HRSA will be targeting its efforts to strengthening linkages between U.S. Public Health Service education programs which provide comprehensive primary care services to the underserved.

Smoke-Free Workplace

The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace; to promote the non-use of all tobacco products; and to promote Public Law 103–227, the Pro-Children Act of 1994, which prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Review Criteria

Applications received will be reviewed by an *ad hoc* review panel using the following criteria:

- the degree to which the proposal contains clearly stated, realistic, cross-cutting, achievable, and measurable objectives;
- the extent to which the proposal includes an integrated methodology compatible with the scope of project objectives, including collaborative relationships with relevant institutions and professional associations;
- the administrative and management capability of the applicant to carry out the Cooperative Agreement; and
- the extent to which budget justifications are complete, appropriate, and cost-effective.

Application Requests

Eligible entities interested in receiving materials regarding this program should notify HRSA. Materials will be sent only to those entities making a request. Requests for proposal instructions and other questions should be directed to: Mr. John R. Westcott, Grants Management Officer, Bureau of Health Professions, HRSA, 5600 Fishers Lane, Room 8C–26, Rockville, Maryland 20857, Telephone: (301) 443–6880.

Completed applications must be returned to the Grants Management Officer at the above address.

Questions concerning programmatic aspects of the Cooperative Agreement must be directed to:

Ronald B. Merrill, M.H.A., Chief, Public Health Branch, Division of Associated, Dental and Public Health Professions, Bureau of Health Professions, HRSA, 5600 Fishers Lane, Room 8C–09, Rockville, Maryland 20857, Telephone: (301) 443–6896

Alexander F. Ross, Sc.D., Office of Public Health Practice/HRSA, Parklawn Building, Room 14–15, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443–4034

Paperwork Reduction Act

The standard application form PHS 6025–1, HRSA Competing Training Grant Application, have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act. The OMB clearance number is 0915–0060.

The deadline date for receipt of application is July 10, 1996. Applications will be considered to be ''on time'' is they are either:

1. *Received on or before* the established deadline date, or

2. *Sent on or before* the established deadline date and received in time for orderly processing. (Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late applications not accepted for processing will be returned to the applicant. In addition, applications which exceed the page limitation and/or do not follow format instructions will not be accepted for processing and will be returned to the applicant.

This program is not subject to the provisions of Executive Order 12372, Intergovernmental Review of Federal Programs (as implemented through 45 CFR part 100). This program is also not subject to the Public Health System Reporting Requirements.

Dated: June 3, 1996.

Ciro V. Sumaya,

*Administrator.*

[FR Doc. 96–14588 Filed 6–7–96; 8:45 am]

BILLING CODE 4160–15–P

**Public Health Service**

**National Toxicology Program (NTP) Board of Scientific Counselors' Meetings; Announcement of NTP Draft Technical Reports Projected for Public Review From December 1996 Through Fall 1998; Request for Public Input**

To earlier inform the public and encourage interested parties to comment or obtain information on projected long-term toxicology and carcinogenesis studies prior to public peer review, the National Toxicology Program (NTP) again publishes in the Federal Register a current listing of draft Technical Reports projected for evaluation by the NTP Board of Scientific Counselors' Technical Reports Review Subcommittee during their next five meetings from December 1996 through Fall 1998. We plan to continue updating the listing with announcements in the Federal Register once or twice a year. The next meeting dates are December 11–12, 1996. Specific dates for 1997 and 1998 meetings will be established at a later time.

The attached Table 1 lists draft Technical Reports for long-term studies on chemicals within known or approximate dates of reviews and includes Chemical Abstracts Service (CAS) registry numbers, primary use, route of administration, species, exposure levels, and NTP report numbers (if assigned).

Technical Reports of short-term toxicity studies are currently reviewed by mail; however, they may be reviewed in open meetings when necessary. The attached Table 2 lists the draft Technical Reports of short-term toxicity studies tentatively projected for review by mail from April 1996 to December 1996 and also includes Chemical Abstracts Service (CAS) registry numbers, primary use, route of administration, species, exposure levels, and NTP report numbers (if assigned).

Those interested in having more information about any of the studies listed in this announcement should contact Central Data Management as early as possible by telephone or by mail at: MD E1–02, NIEHS, P.O. Box 12233, Research Triangle Park (RTP), North Carolina 27709 (919/541–3419). The program would welcome receiving toxicology and carcinogenesis data from completed, ongoing or planned studies by others as well as current production data, human exposure information, and use and use patterns.

The Executive Secretary, Dr. Larry G. Hart, P.O. Box 12233, Research Triangle Park, North Carolina 27709, telephone 919/541–3971, FAX 919/541–0295 will furnish final agendas and other program information prior to a meeting, and summary minutes subsequent to a meeting.

*Attachments*

Dated: May 21, 1996.

Kenneth Olden,

*Director, National Toxicology Program.*

TABLE 1.—SUMMARY DATA FOR TECHNICAL REPORTS SCHEDULED FOR REVIEW AT THE MEETING OF THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM DECEMBER 1996 THROUGH 1998

| Chemical name/cas No. | Use | Route | Species | Exposure levels |
|---|---|---|---|---|
| Chemicals Tentatively Scheduled for Peer Review December 11–12, 1996: | | | | |
| 3′-Azido-3′ -Deoxythymidine (AIDS): | | | | |
| 30516–87–1 | PHAR | GAV | RM | Mice only: 0, 30, 60, or 120 mg/kg; 50/sex. |
| Chloroprene: | | | | |
| 126–99–8 | PLAS | INHAL | RM | R&M: 0, 12.8, 32.0, or 80.0 ppm; 50/sex/species/group. |
| Cobalt Sulfate Heptaphydrate: | | | | |
| 10026–24–1 | PNT | INHAL | RM | R&M: 0, 0.3, 1.0, or 3.0 mg/m$^3$; 50/sex/species/group. |
| Ethylbenzene: | | | | |
| 100–41–4 | RUBR | INHAL | RM | R&M: 0, 75, 250, or 750 ppm (50/sex/species/group). |
| Interferon AD + 3′-Azido-3′ -Deoxythymidine: | | | | |
| (AIDS) | PHAR | SC&GV | MM | Dual routes with both compounds: AZT: 0, 30, 60, or 120 (gav) mg/kg; IFN: 500 or 5000 units 3X/week. |
| Isobutyraldehyde: | | | | |
| 78–84–2 | INTR | INHAL | RM | R&M: 0, 500, 1000, or 2000 ppm (50/sex/species/group). |
| Oxazepam: | | | | |
| 604–75–1 | PHAR | FEED | R | 0, 625, 1250, 2500, 5000, or 10,000 ppm; 50/sex/group. |
| Polyvinyl alcohol: | | | | |
| 9002–89–5 | PHAR | IVAG | M | 25% PVA, vehicle, untreated; 100/group. |
| Primaclone (Primidone): | | | | |
| 125–33–7 | PHAR | FEED | RM | M: 0, 0.03, 0.06, or 0.13% R: 0, 0.06, 0.13, or 0.25% (50/sex/species). |
| Tetrahydrofuran: | | | | |
| 109–99–9 | SOLV | INHAL | RM | R&M: 0, 200, 600, or 1800 ppm (50/sex/species/group). |
| Theophylline: | | | | |
| 58–55–9 | PHAR | GAV | RM | R: 7.5, 25, or 75 mg/kg; 50/group fm: 7.5, 25, or 75 mg/kg; 50/group mm: 15, 50, or 150 mg/kg; 50/group. |
| Chemicals Tentatively Scheduled for Peer Review in Summer 1997: | | | | |
| 1-Chloro-2-Propanol, Technical: | | | | |
| 127–00–4 | INTR | WATER | RM | R: 0, 150, 325, or 650 ppm M: 0, 250, 500, or 1000 ppm (50/sex/group). |

TABLE 1.—SUMMARY DATA FOR TECHNICAL REPORTS SCHEDULED FOR REVIEW AT THE MEETING OF THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM DECEMBER 1996 THROUGH 1998—Continued

| Chemical name/cas No. | Use | Route | Species | Exposure levels |
|---|---|---|---|---|
| Coconut Oil Acid Diethanolamine Condensate: 68603–42–9 | TEXL | SP | RM | R: 0, 50, or 100 mg/kg M: 0, 100, or 200 mg/kg (50 sex/species/group). |
| Diethanolamine: 111–42–2 | TEXL | SP | RM | MR: 0, 16, 32, or 64 mg/kg; FR: 0, 8, 16, or 32 mg/kg; Mice: 0, 40, 80, or 160 mg/kg (50/sex/species/group). |
| Furfuryl alcohol: 98–00–0 | FOOD | INHAL | RM | R&M: 0, 2, 8, or 32 ppm (50/sex/species/group). |
| Lauric Acid Diethanolamine Condensate: 120–40–1 | DTRG | SP | RM | R: 0, 50, or 100 mg/kg M: 0, 100, or 200 mg/kg (50/sex/species/group). |
| Oleic Acid Diethanolamine Condensate: 93–83–4 | COSM | SP | RM | R: 0, 50, or 100 mg/kg; 50/sex/group M: 0, 15, or 30 mg/kg; 55/sex/group. |
| Pyridine: 110–86–1 | SOLV | WATER | RMR | R: 0, 100, 200, or 400 ppm MM: 0, 250, 500, or 1000 ppm FM: 125, 250, or 500 ppm MWR: 0, 100, 200, or 400 ppm (50/sex/group). |
| Chemicals Tentatively Scheduled for Peer Review Fall 1997: | | | | |
| Ethylene Glycol Monobutyl Ether (EGMBE): 111–76–2 | SOLV | INHAL | RM | R: 0, 31, 62.5, or 125 ppm M: 0, 62.5, 125, or 250 ppm; 50/sex/species. |
| Isobutene: 115–11–7 | RUBR | INHAL | RM | R&M: 0, 500, 2000, or 8000 ppm (50/sex/species/group). |
| Isoprene: 78–79–5 | RUBR | INHAL | R | R: 0, 220, 700, or 7000 ppm; 50/sex/group. |
| Pentachlorophenol, purified: 87–86–5 | PEST | FEED | R | R: 0, 200, 400, or 600 ppm; 50/sex/group—1000 ppm stop study (60/sex). |
| Chemicals Tenatively Scheduled for Peer Review Summer 1998: | | | | |
| Gallium Arsenide: 1303–00–0 | ELEC | INHAL | RM | R: 0, 0.01, 0.1, or 1.0 mg/m$^3$; 50/sex/group M: 0, 0.1, 0.5, or 1.0 mg/m$^3$; 50/sex/group. |
| Methyleugenol: 93–15–2 | FOOD | GAV | RM | R&M: 0, 37, 75, or 150 mg/kg (50/sex/species/group). |
| Oxymetholone: 434–07–1 | PHAR | GAV | RM | MR: 0, 3, 30, or 150 mg/kg; FR: 0, 3, 30, or 100 mg/kg. |
| Chemicals Tentatively Scheduled for Peer Review Fall 1998: | | | | |
| Indium Phosphide: 22398–80–7 | ELEC | INHAL | RM | R&M: 0, 0.03, 0.1, or 0.3 mg/m$^3$. |

TABLE 2.—SHORT-TERM TOXICITY STUDIES SCHEDULED FOR REVIEW BY THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM APRIL 1996 THROUGH 1998

| Chemical name/CAS No. | Use | Route | Species | Exposure levels |
|---|---|---|---|---|
| Short-Term Toxicity Studies Tentatively Scheduled for Peer Review April 1996: | | | | |
| Magnetic Fields (EMF): Electromag | ELEC | WB | RM | 60 hz magnetic fields—20 mg, 58 2g, 10 g continuous and 10 g intermittent; 10/group. |
| Methacrylonitrile: 126–98–7 | PLAS | GAV | RM | R: 0, 7.5, 15.0, 30.0, 60.0, 120.0 47 mg/kg/day; M: 0, 0.75, 1.5, 3.0, 6.0, 12.0 mg/kg/day; Rats: 20/grp; mice: 10/grp. |
| Methapyrilene Hydrochloride: 135–23–9 | PHAR | FEED | R | Male Rats: 0, 50, 100, 250, 46 1000 ppm; 40/grp. |

TABLE 2.—SHORT-TERM TOXICITY STUDIES SCHEDULED FOR REVIEW BY THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM APRIL 1996 THROUGH 1998—Continued

| Chemical name/CAS No. | Use | Route | Species | Exposure levels |
|---|---|---|---|---|
| Short-Term Toxicity Studies Tentatively Scheduled for Peer Review May 1996: | | | | |
| M-Chloroaniline: | | | | |
| 108–42–9 | INTR | GAV | RM | R&M 0, 10, 20, 40, 80, 160 43 mg/kg, 20/grp (rats); 10/grp (mice). |
| O-Chloroaniline: | | | | |
| 95–51–2 | DYE | GAV | RM | R&M 0, 10, 20, 40, 80, & 160 43 mg/kg, 20/grp (rats); 10/grp (mice). |
| Short-Term Toxicity Studies Tentatively Scheduled for Peer Review June 1996: | | | | |
| AZT+Methadone HCL (AIDS): | | | | |
| Aztmethcomb | PHAR | GAV | MM | AZT: 200, 400, or 800 mg/kg/day with Methadone HCL: 5, 15, or 30 mg/kg/day. |
| 2′, 3′-Dideoxycytidine (AIDS initiative): | | | | |
| 7481–89–2 | PHAR | GAV | MM | Female mice only: 500, 1000 mg/kg/day. |
| 3, 3′, 4, 4′-Tetrachloroazobenzene: | | | | |
| 14047–09–7 | HERB | GAV | RM | R&M: 0, 0.1, 1.0, 3.0, 10, or 30 mg/kg body weight (M&F; 10/group). |
| 1, 1, 2, 2-Tetrachloroethane | SOLV | GAV | RM | |
| 1, 1, 2, 2-Tetrachloroethane: | | | | |
| 79–34–5 | SOLV | MICRO | RM | R&M; R:untreated control, vehicle control, 18, 37, 75, 150, or 300 mg/kg body wt/day; M: untreated control, vehicle control, 88, 175, 350, 700, or 1400 mg/kg body wt/day; 10/group/sex. |
| Short-Term Toxicity Studies Tentatively Scheduled for Peer Review August 1996: | | | | |
| 1, 1, 1-Trichloroethane: | | | | |
| 71–55–6 | SOLV | MICRO | RM | R&M: 0, 0.5, 1.0, 2.0, 4.0, 41 and, 8.0% (10/S/S). |
| Short-Term Toxicity Studies Tentatively Scheduled for Peer Review December 1996: | | | | |
| CIS & TRANS 1,2-Dichloroethylene: | | | | |
| 540–59–0 | SOLV | MICRO | RM | 55. |
| CIS-1, 2-Dichloroethylene: | | | | |
| 156–59–2 | SOLV | MICRO | RM | 55. |
| TRANS-1, 2-Dichloroethylene: | | | | |
| 156–60–5 | SOLV | MICRO | RM | 55. |
| TRANS-1, 2-Dichloroethylene: | | | | |
| 156–60–5 | SOLV | GAV | RM | 55. |
| TRANS-1, 2-Dichloroethylene: | | | | |
| 156–60–5 | SOLV | MICRO | RM | R&M: untreated control, vehicle control, 3125, 6250, 12,500, 25,000, or 50,000 ppm; 10/group/sex. |

Abbreviations used: in this report:

| Use | Primary use category |
|---|---|
| COMT | Contaminates and/or Impurities. |
| COSM | Cosmetics, Perfumes, Fragrances, Hair Preparations. |
| DTRG | Detergents and Cleaners. |
| DYE | As or in Dyes, Inks, and Pigments. |
| ELEC | In Electrical and/or Dielectric Systems. |
| FOOD | Food, Beverages, or Additives. |
| HERB | Herbicide(s). |
| INTR | Chemical Intermediate or Catalyst. |
| PEST | Pesticides, General or Unclassified. |
| PHAR | Pharmaceuticals or Intermediates. |
| PLAS | As or in Plastics. |
| PNT | Paint Ingredient. |
| RUBR | Rubber Chemical. |
| SOLV | Vehicles and Solvents. |
| TEXL | In Manufacture of Textiles. |

| Route | Route of administration |
|---|---|
| FEED | Dosed-Feed. |
| GAV | Gavage. |
| INHAL | Inhalation. |
| IP/IJ | Intraperitoneal Injection. |
| IVAG | Intravaginal. |
| MICRO | Microencapsulation in Feed. |
| SC&GV | Subcutaneous Inj.+Gavage. |
| SP | Topical. |
| WATER | Dosed-Water. |
| WB | Whole Body Exposure. |

| Spec | | Species |
|---|---|---|
| R | = | Rats. |
| M | = | Mice. |

[FR Doc. 96–14149 Filed 6–7–96; 8:45 am]

BILLING CODE 4140–01–M

## Substance Abuse and Mental Health Services Administration

### Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a list of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443–0525.

FY 1997/1998 Substance Abuse Prevention and Treatment Block Grant Application Format—Revision of a currently approved collection—The Public Health Service Act (42 U.S.C. 300x 1–9) authorizes block grants to States for the purpose of providing prevention and treatment services.